Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?. | Int. J. Med. Sci. 2004 1 2 116-125 116 International Journal of Medical Sciences Research paper ISSN 1449-1907 2004 1 2 116-125 2004 Ivyspring International Publisher. All rights reserved A Randomized Study of Epithelial Ovarian Cancer Is Received Accepted Published Chemotherapy Useful after Complete Remission . Nicoletto S. Tumolo C. Falci M. Donach E. Visona A. Rosabian O. Nascimben . Cima O. Vinante P. Azzoni . Fiorentino GOCCNE Group Gruppo Oncologico Cooperativo Clinico Nord-Est ovaio Padua Italy Abstract Objective. The aim of this study is to verify whether consolidation chemotherapy with Cisplatin improves disease-free survival and or overall survival in patients affected by epithelial ovarian cancer. Methods. A multicenter study examined 122 randomized patients in complete remission as judged by laparoscopy or laparotomy following first-line chemotherapy consisting of ACy Adriamycin Cyclophosphamide PCy Cisplatin Cyclophosphamide or Mitoxantrone Carboplatin. Sixty-one of these patients were treated with 3 cycles of 5-Fluorouracil FU 500 mg m2 for 5 days followed by Cisplatin at 100 mg m2 on the 6th or 7th day every 28 days the other 61 received no further treatment nihil group . Results. Sixty patients in the Cisplatin arm were evaluable. There were 36 relapses in the FU Cisplatin arm and 30 in the nihil arm. Peritoneal relapses were 25 for Cisplatin treatment vs. for nihil. There were 29 deaths in the Cisplatin arm vs. 27 for nihil. Median overall survival time 95 months with Cisplatin vs. 96 months in the nihil group and median disease-free survival 66 months with Cisplatin vs. 73 in the nihil group were similar in both arms p and p respectively . There were no significant differences in tumor stage and grade between the two arms. Seven patients presented a second neoplasm during follow-up six in the nihil arm but only one patient in the Cisplatin arm. Death in these patients was due to .
